^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Bladder Cancer
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/09/2021
    Excerpt:
    Bladder Cancer: Avelumab is also recommended as a maintenance therapy following first-line platinum-containing treatment.